With 300% rally in 5 years, multibagger stock in focus on Monday | Here's why - Details from exchange filing
Sudarshan Pharma's strategic acquisition of a 9.5% stake in Med Therapy Biotechnology Inc. signals its intent to penetrate the lucrative US oncology market, ...